




RealRate

PHARMACEUTICAL 2012

GYRE Therapeutics INC
Rank 66 of 196

CATALYST
BIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points. The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 80% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	198,693
Cost of Goods Sold	0
Intangible Assets	132
Liabilities, Current	78,611
Liabilities, Non-Current	1,986
Other Assets	59,301
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,241
Other Net Income	1,216
Other Revenues	97,637
Property and Equipment	0
Research and Development	95,215
Selling, General and Administrative Expense	12,167

Output Variable	Value in 1000 USD
Assets	258,126
Liabilities	83,838
Expenses	107,382
Revenues	97,637
Stockholders Equity	174,288
Net Income	-8,529
Comprehensive Net Income	-8,529
BaseVar	274,100
ECR before Limited Liability	217%
Economic Capital Ratio	314%